CYBERMED LIFE - ORGANIC  & NATURAL LIVING

Dietary Modification - Low Carbohydrate-Ketogenic

Ketogenic diet in a patient with congenital hyperinsulinism: a novel approach to prevent brain damage📎

Written by CYBERMED LIFE NEWS
Attachments:
Download this file (Ketogenic diet in a patient with congenital hyperinsulinism - a novel approach to prevent brain damage..pdf)Ketogenic diet in a patient with congenital hyperinsulinism - a novel approach to prevent brain damage..pdf[Ketogenic diet in a patient with congenital hyperinsulinism - a novel approach to prevent brain damage.]1735 kB
facebook Share on Facebook
Abstract Title:

Ketogenic diet in a patient with congenital hyperinsulinism: a novel approach to prevent brain damage.

Abstract Source:

Orphanet J Rare Dis. 2015 ;10(1):120. Epub 2015 Sep 24. PMID: 26399329

Abstract Author(s):

Arianna Maiorana, Lucilla Manganozzi, Fabrizio Barbetti, Silvia Bernabei, Giorgia Gallo, Raffaella Cusmai, Stefania Caviglia, Carlo Dionisi-Vici

Article Affiliation:

Arianna Maiorana

Abstract:

BACKGROUND: Congenital hyperinsulinism (CHI) is the most frequent cause of hypoglycemia in children. In addition to increased peripheral glucose utilization, dysregulated insulin secretion induces profound hypoglycemia and neuroglycopenia by inhibiting glycogenolysis, gluconeogenesis and lipolysis. This results in the shortage of all cerebral energy substrates (glucose, lactate and ketones), and can lead to severe neurological sequelae. Patients with CHI unresponsive to medical treatment can be subjected to near-total pancreatectomy with increased risk of secondary diabetes. Ketogenic diet (KD), by reproducing a fasting-like condition in which body fuel mainly derives from beta-oxidation, is intended to provide alternative cerebral substrates such ketone bodies. We took advantage of known protective effect of KD on neuronal damage associated with GLUT1 deficiency, a disorder of impaired glucose transport across the blood-brain barrier, and administered KD in a patient with drug-unresponsive CHI, with the aim of providing to neurons an energy source alternative to glucose.

METHODS: A child with drug-resistant, long-standing CHI caused by a spontaneous GCK activating mutation (p.Val455Met) suffered from epilepsy and showed neurodevelopmental abnormalities. After attempting various therapeutic regimes without success, near-total pancreatectomy was suggested to parents, who asked for other options. Therefore, we proposed KD in combination with insulin-suppressing drugs.

RESULTS: We administered KD for 2 years. Soon after the first six months, the patient was free of epileptic crises, presented normalization of EEG, and showed a marked recover in psychological development and quality of life.

CONCLUSIONS: KD could represent an effective treatment to support brain function in selected cases of CHI.


We use cookies on our website. Some of them are essential for the operation of the site, while others help us to improve this site and the user experience (tracking cookies). You can decide for yourself whether you want to allow cookies or not. Please note that if you reject them, you may not be able to use all the functionalities of the site.